A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis

Table 3 Participants’ baseline demographic characteristics and symptom scores

Variable	Overall (N = 66)	Variable	Overall (N = 66)
Age (yrs)		Baseline sneezing score
Mean	35.0	Mean	2.1
Std.	9.88	Std.	0.97
Median	34.5	Median	2.0
Min. to Max.	21-63	Min. to Max.	0-3
Gender		Baseline runny nose score
Male	27 (41%)	Mean	2.7
Female	39 (59%)	Std.	0.44
Ethnicity		Median	3.0
Hispanic	0 (0%)	Min. to Max.	2-3
Not Hispanic	66 (100%)	Baseline nasal itching score
Race		Mean	2.6
Caucasian	64 (97%)	Std.	0.55
Black	0 (0%)	Median	3.0
Asian	2 (3%)	Min. to Max.	1-3
American Indian/Alaska Native	0 (0%)	Baseline stuffy nose score
Native Hawaiian/Other Pacific Islander	0 (0%)	Mean	2.6
Other	0 (0%)	Std.	0.52
Height (cm)		Median	3.0
Mean	168.2	Min. to Max.	1-3
Std.	8.70	Baseline teary eyes score
Median	168.0	Mean	2.0
Min. to Max.	153-188	Std.	0.73
Weight (kg)		Median	2.0
Mean	79.6	Min. to Max.	1-3
Std.	16.77	Baseline itchy eyes score
Median	79.0	Mean	2.4
Min. to Max.	50-125	Std.	0.75
BMI (kg/m ² )		Median	3.0
Mean	28.11	Min. to Max.	1-3
Std.	5.478	Baseline total nasal symptom score
Median	27.04	Mean	7.4
Min. to Max.	19.1-42.8	Std.	1.21
		Median	7.0
		Min. to Max.	5-9

Baseline is the 90-minute evaluation after the beginning of the allergen challenge for the baseline period prior to dosing period 1.

ISSN: 1710-1492